Professor
Hermann Memorial Hospital
Houston, TX, United States
Dr. Baha M. Sibai, Professor, Department of the Obstetrics, Gynecology and Reproductive Sciences which is part of the McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth). He is the Director of the largest Maternal‐Fetal Medicine fellowship program in the country, and has active clinical practices at Memorial Hermann‐Texas Medical Center and Lyndon B. Johnson Hospital, part of Harris Health System. Dr. Sibai has been awarded the Lifetime Achievement Award by the Society for Maternal‐Fetal Medicine, and the 2018 ACOG Hall of Fame Al-Star Status. He is a founding member and past president of the North American Society for the Study of Hypertension in Pregnancy and past president of the International Society for the Study of Hypertension and Pregnancy. He is a member of the MFM Units Network for more than twenty years and, he has served on the Task force for Hypertension and written/co‐authored numerous research studies on preeclampsia. In addition, he served as an examiner for the American Board of Obstetrics and Gynecology from 1995‐2013.
Dr. Sibai is an internationally recognized researcher and clinician in Maternal‐Fetal Medicine at The McGovern Medical School – UTHealth Houston in the Department of Obstetrics, Gynecology and Reproductive Sciences. Dr. Sibai has an extensive history of grant funding from the National Institutes of Health (NIH) and Centers for Disease Control and has led several multi‐center clinical trials.
Dr. Sibai is a leading authority in the care and treatment of women with preeclampsia, eclampsia, pre‐ term birth, rare obstetric syndromes, medical and surgical disorders in pregnancy and medical and obstetric emergencies during pregnancy and childbirth including postpartum hemorrhage. He has published more than 650 peer‐reviewed articles in various scientific journals as well as numerous chapters in text books, and was the Editor of several text books.
Tuesday, February 13, 2024
2:30 PM – 2:45 PM
(43) 162 mg versus 81 mg Aspirin for High-risk Obese Individuals: An Open Label RCT (ASPREO)
Wednesday, February 14, 2024
10:30 AM – 10:45 AM
(70) Management Approaches for Placenta Accreta Spectrum - Not a one size fits all approach
Wednesday, February 14, 2024
4:15 PM – 4:30 PM